We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Next-Generation DNA Sequencer Platform Is Small and Affordable

By LabMedica International staff writers
Posted on 02 Jun 2010
A benchtop next-generation DNA sequencing platform is ideally suited for labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial-genome sequencing, metagenomic analysis, as well as novel pathogen detection.

The GS Junior System includes a suite of high-performance data analysis software, offering a solution for scientists who are less experienced in DNA sequencing technologies and bioinformatics. More...
The software package includes tools for de novo genome and transcriptome assembly and mapping, as well as amplicon variant analysis for the identification of rare variants in targeted sequencing studies.

Roche (Basel, Switzerland) announced the global launch of the GS Junior System, the company's new DNA sequencing platform. Developed by 454 Life Sciences (Branford, CT, USA), a Roche company, the system provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency, and price competitiveness, small and medium sized laboratories worldwide will have access to Roche's state-of-the-art sequencing capabilities at an affordable price.

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double-digit growth expected for the next several years.

Roche's Genome Sequencer FLX System has enabled hundreds of scientific discoveries, including the identification of novel pathogenic viruses, the analysis of ancient DNA from Neanderthal man and the wooly mammoth, and the characterization of microbial communities in the human gut.

"Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turnaround time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications,” said Daniel O'Day, COO of Roche Diagnostics (Indianapolis, IN, USA).

Roche is a leader in research-focused healthcare with combined strengths in diagnostics and pharmaceuticals. It is also a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche
454 Life Sciences
Roche Diagnostics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.